AU1
Asset Logo

The Agency Group Australia Ltd

๐Ÿ‡ฆ๐Ÿ‡บ ASX

๐Ÿ  REAL ESTATE

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

-12.54%
Annual Growth

5 years average annual growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

0
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

The Agency Group Australia Ltd. engages in providing real estate and financial services. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-12-18. The Companyโ€™s principal activity consists of real estate services and related activities. The company segments include Real Estate Property Services and Mortgage Origination Services. Its Real Estate and Property Services segment is engaged in the provision of real estate services including selling of property, settlement agent services, and property management. Its Mortgage Origination Services segment is engaged in the provision of mortgage broking services. The firm's wholly owned subsidiaries include Agency Partners WA Pty Ltd, Ausnet Financial Planning Services Pty Ltd, Ausnet Financial Pty Ltd, Ausnet Property Investment Fund Pty Ltd, Ausnet Real Estate Services Pty Ltd, Bushby & Co. Pty Ltd, Jelina Holdings Pty Ltd, Move Property Solutions Pty Ltd, The Agency Auctions NSW Pty Ltd, The Agency Canberra Pty Ltd, The Agency Commercial Real Estate Pty Ltd, and The Agency Marketing Pty Ltd.

๐Ÿ“ˆ Performance

Price History

+316.67%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.03

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in AU1

0

๐Ÿ“Š Total Capital Earnings

N/A

๐Ÿ”ƒ Average investment frequency

N/A

๐Ÿ’ต Average investment amount

N/A

โฐ Last time a customer invested in AU1

375 days
AU1 investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

๐Ÿ™‹ Legal gender of investors

Female

Male

Pearlers who invest in AU1 also invest in...

SPDR S&P World Ex Aus Carbon Control (Hedged) Fund

WXHG

WXHG.AX was created on 2013-07-08 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The SPDR S&P World ex Australia (Hedged) Fund seeks to closely track, before fees and expenses, the returns of the S&P Developed ex Australia LargeMidCap AUD Hedged Index.

๐Ÿ™Œ Performance (5Yr p.a)

2.03%

๐Ÿ“Š Share price

$25.90 AUD

๐Ÿ’ฐ HIGH DIVIDEND

Find Out More

WXOZ.AX was created on 2013-03-18 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 405.4m in AUM and 763 holdings. The Investment Objective of SPDR S&P World Ex Australia Carbon Control Fund is to match the performance of its Index before fees and other costs.

๐Ÿ™Œ Performance (5Yr p.a)

7.66%

๐Ÿ“Š Share price

$47.30 AUD

๐Ÿค– TECHNOLOGY

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

13.28%

๐Ÿ“Š Share price

$134.96 AUD

๐ŸŒ GLOBAL

โ›ณ๏ธ DIVERSIFIED

๐Ÿค– TECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH

MVOL.AX was created on 2016-10-11 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 19.74m in AUM and 94 holdings. The fund aims to provide investors with the performance of the MSCI Australia IMI Select Minimum Volatility (AUD) Index, before fees and expenses.

๐Ÿ™Œ Performance (5Yr p.a)

1.75%

๐Ÿ“Š Share price

$32.51 AUD

โ›ณ๏ธ DIVERSIFIED

๐Ÿ’ธ FINANCIALS

QHAL.AX was created on 2019-03-21 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. QHAL.AX seeks to provide investors with access to a diversified portfolio of quality international companies from developed markets (ex-Australia) hedged into Australian dollars with the aim of providing investment returns, before fees and other costs, which track the performance of the Index.

๐Ÿ™Œ Performance (5Yr p.a)

13.76%

๐Ÿ“Š Share price

$48.18 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

Audeara Ltd. engages in the development of noise-cancelling consumer headphones. The company is headquartered in Fortitude Valley, Queensland. The company went IPO on 2021-05-18. The firm specializes in listening solutions for people with hearing challenges. Its principal activity is development of hearing health technology. Its headphones deliver personalized audio to users via Bluetooth headphones. Its headphones are categorized as an assistive listening device (ALD), which can be paired with its mobile application called the Audeara App. Its technology is compatible for use with cochlear implants and hearing aids. The Audeara App uses a personalized algorithm to calibrate the headphones for an individualโ€™s hearing profile. This provides clear sound quality for video conferencing and telephone calls and using mainstream applications like watching television, listening to music, and gaming. Its products include A-01 Headphones, BT-01 Transceiver, A-02 Headphones and A-02 TV Bundle. The company sells its products through distributors and resellers in Australia and North America, and via e-commerce channels.

๐Ÿ“Š Share price

$0.04 AUD

๐Ÿ›๏ธ CONSUMER

AUB Group Ltd.Provides equity based insurance broker network.It operates under the following segments: Australian Broking, New Zealand, Australian Agencies, and Support Service. The company is headquartered in Sydney, New South Wales and currently employs 2,433 full-time employees. The company went IPO on 2005-11-16. Its segments include Australian Broking, New Zealand Broking, Agencies, Tysers and Support service. The Australian Broking segment assesses the insurable risks and risk appetite of customers and sources relevant insurance products from insurers and underwriters which meet the needs of the customer. The Agencies segment assesses, on behalf of the insurer, the risk profile of the end customer and pricing of policies requested by brokers. The New Zealand Broking segment provides broking services within the New Zealand market. The Tysers segment includes wholesale and retail broking and managing general agents. The Support Services segment provides a range of services to support the Australian Broking, Agencies, and New Zealand Broking and Tysers segments, and external clients. Retail broking provides retail broking services within the United Kingdom market.

๐Ÿ™Œ Performance (5Yr p.a)

32.75%

๐Ÿ“Š Share price

$31.18 AUD

๐Ÿ‘ฉโ€๐Ÿ’ผ INSURANCE

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿ“Š Share price

$0.00 AUD

Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The firm's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The firm's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.

๐Ÿ™Œ Performance (5Yr p.a)

2.23%

๐Ÿ“Š Share price

$0.09 AUD

๐Ÿงฌ BIOTECHNOLOGY

Compare
Add to watchlist